http://www.guardian.co.uk/science/2003/jun/11/sciencenews.medicineandhealth
According to Alastair Benbow, Glaxo's head of European psychiatry, the trials on a total of 1,697 under-18s found that the drug was effective for social anxiety disorder and obsessive compulsive disorder, but not for depression.
He said the company had submitted the analysis of the nine trials to the MHRA as a matter of routine. It had not supplied the results of each trial as it finished. "We provide information as a package," he said.
what the MHRA said - http://www.mhra.gov.uk/home/groups/pl-p/documents/websiteresources/con019508.pdf
No comments:
Post a Comment
Note: only a member of this blog may post a comment.